
USD
+$0.00
(+0.00%
)At Close (As of Oct 24, 2025)
$218.83B
Market Cap
13.43
P/E Ratio
6.49
EPS
$101.36
52 Week High
$71.87
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $49B |
| Total Revenue | $64B |
| Cost Of Revenue | $15B |
| Costof Goods And Services Sold | $15B |
| Operating Income | $20B |
| Selling General And Administrative | $7.7B |
| Research And Development | $18B |
| Operating Expenses | $29B |
| Investment Income Net | - |
| Net Interest Income | -$856M |
| Interest Income | $415M |
| Interest Expense | $1.3B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.5B |
| Income Before Tax | $20B |
| Income Tax Expense | $2.8B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $17B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $21B |
| Ebitda | $26B |
| Net Income | $17B |
| Field | Value (USD) |
|---|---|
| Total Assets | $117B |
| Total Current Assets | $39B |
| Cash And Cash Equivalents At Carrying Value | $13B |
| Cash And Short Term Investments | $13B |
| Inventory | $6.1B |
| Current Net Receivables | $10B |
| Total Non Current Assets | $78B |
| Property Plant Equipment | $25B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $16B |
| Intangible Assets Excluding Goodwill | $16B |
| Goodwill | $22B |
| Investments | - |
| Long Term Investments | $463M |
| Short Term Investments | $447M |
| Other Current Assets | $8.7B |
| Other Non Current Assets | - |
| Total Liabilities | $71B |
| Total Current Liabilities | $28B |
| Current Accounts Payable | $4.1B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.9B |
| Total Non Current Liabilities | $42B |
| Capital Lease Obligations | - |
| Long Term Debt | $34B |
| Current Long Term Debt | $2.6B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $38B |
| Other Current Liabilities | $17B |
| Other Non Current Liabilities | $6.5B |
| Total Shareholder Equity | $46B |
| Treasury Stock | - |
| Retained Earnings | $63B |
| Common Stock | $1.8B |
| Common Stock Shares Outstanding | $2.5B |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $21B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $4.5B |
| Capital Expenditures | $3.4B |
| Change In Receivables | - |
| Change In Inventory | -$835M |
| Profit Loss | - |
| Cashflow From Investment | -$7.7B |
| Cashflow From Financing | -$7B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $7.8B |
| Dividend Payout Common Stock | $7.8B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$1.3B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $17B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $49B |
| Total Revenue | $64B |
| Cost Of Revenue | $15B |
| Costof Goods And Services Sold | $15B |
| Operating Income | $20B |
| Selling General And Administrative | $7.7B |
| Research And Development | $18B |
| Operating Expenses | $29B |
| Investment Income Net | - |
| Net Interest Income | -$856M |
| Interest Income | $415M |
| Interest Expense | $1.3B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.5B |
| Income Before Tax | $20B |
| Income Tax Expense | $2.8B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $17B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $21B |
| Ebitda | $26B |
| Net Income | $17B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-09-15 |
| Declaration Date | 2025-07-22 |
| Record Date | 2025-09-15 |
| Payment Date | 2025-10-07 |
| Amount | 0.81 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Merck & Company Inc. is a prominent American multinational pharmaceutical corporation headquartered in Kenilworth, New Jersey, celebrated for its dedication to enhancing global health through cutting-edge pharmaceuticals and vaccines. Established in 1891 as the U.S. subsidiary of the German Merck Group, Merck has a rich history of scientific innovation, focusing on critical therapeutic areas such as oncology, infectious diseases, and cardiovascular health. The company boasts a robust pipeline of novel therapies and a strong commitment to research and development, positioning itself as a leader in the biopharmaceutical sector. By prioritizing patient outcomes and healthcare accessibility, Merck is well-equipped to navigate the evolving healthcare landscape, driving both growth and innovation through its scientific prowess and strategic collaborations.